Cabazitaxel Spirig HC 60 mg/3 ml, Konzentrat zur Herstellung einer Infusionslösung

7680689590011 CH-68959 Konzentrat
Cabazitaxel Spirig HC 60 mg/3 ml, Konzentrat zur Herstellung einer Infusionslösung
Cabazitaxel Spirig HC 60 mg/3 ml, Konzentrat zur Herstellung einer Infusionslösung
Cabazitaxel Spirig HC 60 mg/3 ml, Konzentrat zur Herstellung einer Infusionslösung
1 / 3
google

Article details

Package size
3
Selling units
3
Measure
ml
Galenic form
Konzentrat
Galenic group
Tinkturen/Desinfektion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
16/09/2025
Summary of Product Characteristics
Français
16/09/2025
Summary of Product Characteristics
Italien
16/09/2025

Detailed composition

Substance Quantity Type Category
(N/A)
60.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance HNIDK
(N/A)
1185.0 MG Substance HBESI
(N/A)
- Substance HNIDK

Reimbursement information

Public price
CHF 2690.90
Specialties list
Yes
Generic
Yes

Reimbursement limitation

SL addition date: 01/11/2023

Authorization holder

Spirig HealthCare AG

4622 Egerkingen

Authorization information

Swissmedic authorization number
68959
Drug name
Cabazitaxel Spirig HC, Konzentrat zur Herstellung einer Infusionslösung
Galenic form
KOINF
ATC Code
L01CD04
Authorization status
Z
Dispensing category
A
First authorization
01/12/2022
Authorization expiration date
30/11/2027
IT Number
07.16.1.
Domain
Human medicine
Field of application
Zytostatikum

Package details

Description (FR)
CABAZITAXEL Spirig HC conc perf 60 mg/3ml flac
Description (DE)
CABAZITAXEL Spirig HC Inf Konz 60 mg/3ml Durchstf
Market launch
01/12/2022
Narcotic (BTM)
No

Original drug

Jevtana, solution à diluer et solvant pour solution pour perfusion
GTIN: 7680615430015
CHF 2942.05
View original